GU oncology at UCSF | MSKCC fellowship alum | cancer immunology and metabolism | tweets are mine
Joined April 2009
- Tweets 68
- Following 130
- Followers 269
- Likes 185
11 Photos and videos
Kelly Fitzgerald retweeted
16 Nov 2025
Sunrise run at #IKCS25 with amazing colleagues ✨ No better way to come together, recharge, and stay grounded in why we do this work. Grateful for this community and for every step we take to push kidney cancer care forward. #GUonc #KidneyCancer
1
11
1,152
15 Nov 2025
Great talk by @MdArpita #ucsf at #IKCSNA25 succinctly summarizing options in the challenging setting of IO resistance in RCC. We are looking ahead to earlier implementation of HIF2a blockade and earlier access to trials for our patients. @KidneyCancer
1
2
19
3,814
Kelly Fitzgerald retweeted
23 May 2025
From the May issue: 'Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in RCC brnw.ch/21wSSDz
By Miya Hugaboom, @lena__wirth, Kelly Street, @nruthen16, Michael Atkins, Catherine Wu, @BraunMDPhD
9
29
5,053
Kelly Fitzgerald retweeted
14 Apr 2025
Interested in myeloid cell anti-tumor immunity? I’ll be presenting at @theNCI Rising Scholars Seminar Series on 17 Apr our work on Fc-optimized CD40 Agonistic Antibody and TLS formation and induction of Systemic Antitumor Immunity cassyni.com/events/Eg84FXZjL…
2
7
23
2,444
(1/3) Check out our multicenter, IIT of sitravatinib nivolumab after ICI in patients with metastatic ccRCC shorturl.at/qGWgy This trial was terminated early (14 of 88 planned) but built upon our group’s experience with sitravatinib led by @PavlosMsaouel
1
18
35
2,827
Kelly Fitzgerald retweeted
26 Mar 2025
Federal #kidneycancer research funding drops from $50 million to ZERO after 57% cut to CDMRP. All but 12 of the 35 disease research programs saw funding eliminated for 2025, including the Kidney Cancer Research Program. More about the impact on our blog. bit.ly/4hoXnCq
1
19
16
6,321
Kelly Fitzgerald retweeted
12 Mar 2025
UPDATE 3/12: Last night the House voted to cut 57% of federally funded medical and cancer research through the CDMRP. Vote moves on to Senate and, if passed, to be signed into law by the President.
More details: kidneycancer.org/protect-fed…
11 Mar 2025
🚨Protect Federal Funding for Kidney Cancer Research🚨
Right now, @CDMRP is facing a devastating 57% cut that directly impacts federal #kidneycancer research funding. Tell your reps to vote in support of continued funding.
Take action NOW - bit.ly/4hoXnCq
12
10
2,298
Kelly Fitzgerald retweeted
21 Sep 2024
Happening Today **Kidney Cancer Association's 2024 Virtual Patient Summit** for education and support! 🎗️🧠
📅 Learn more and register here: [kidneycancer.org/patient-edu…]
#KidneyCancer #PatientEducation @KidneyCancer @may_alley @DrRanaMcKay @KidneyCancerDoc @KellyNFitz
1
2
3
438
Kelly Fitzgerald retweeted
2 Jun 2024
3
21
5,354
1 Jun 2024
Interesting to consider a ‘very favorable risk’ subgroup of ccRCC patients and the role of VEGFR targeted therapies here. How will HIF2a blockade perform in these patients?
#MartinZarba @DrDanielHeng @UCalgaryMed with IMDC very/favorable risk #kidneycancer — all regimens w excellent survival. Ipi-nivo doublet falls short in very favorable risk RCC. @ASCO #ASCO24 @OncoAlert
4
345
1 Jun 2024
Congrats to @dsahil320 Sahil Doshi for this retrospective analysis of outcomes on first-line therapy in >100 patients with #chromophobe rcc. Looking forward to seeing longer term follow-up in patients in the doublet cohorts. @MVossMD @NazliDizman @OncHahn @dreaknezevic
3
17
550
Kelly Fitzgerald retweeted
27 Dec 2023
Thoroughly enjoyed reading this overview of selected molecularly defined aggressive #kidneycancer subtypes by @Unclassified1 👉 journals.lww.com/anatomicpat… #RenalMedullaryCarcinoma #RareCancers #HLRCC #endRMC @KidneyCancer @RmcAlliance @RMCAwareness @renalmedullary @RareCancerRF
1
12
46
3,340
Kelly Fitzgerald retweeted
15 Dec 2023
Big news for bladder cancer in US!
“On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”
2
26
116
8,900
Kelly Fitzgerald retweeted
Great news for our patients w #kidneycancer!! Belzutifan now approved in refractory disease based on #LITESPARK005 data from @AlbigesL et al. @kcCURE @KidneyCancer @kidneycan
14 Dec 2023
JUST IN: @US_FDA approved belzutifan (HIF2 inhibitor) in advanced renal cell carcinoma (RCC) following PD1 and VEGF inhibitors!
A great day for the field and a new option for our Kidney Cancer patients!!!!
Via @ASCO #FDAAlerts @OncoAlert
Study presented at @myESMO #ESMO3 by @AlbigesL
11
38
5,214
Kelly Fitzgerald retweeted
12 Dec 2023
Exited to have Dr. Kelly Fitzgerald @KellyNFitz speak at UCSF #CardioOnc conference this THU. Discussion of RCC/kidney cancer & CardioOnc. Focus on VEGF/HIF inhibitors and immune checkpoints! @UCSFCardiology @UCSFCancer @baik_alan @MandarArasMD
9
36
2,795
11 Nov 2023
Happy to share our findings at #IKCSNA23! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.
8
21
2,304
Kelly Fitzgerald retweeted
10 Nov 2023
Zanzalitinib with activity in refractory RCC with manageable safety profile even in those patients who had previously received cabozantinib @montypal @DrChoueiri @KidneyCancer
16
45
5,831
Kelly Fitzgerald retweeted
21 Oct 2023
Belzutifan vs everolimus in pretreated RCC #ESMO23: 25% ⬆️ in PFS, OS HR = 0.88 (95% CI 0.73-1.07) with RR=23% vs 3% & 25-45% ⬆️ in time to ⬇️ QOL. Tox of note: hypoxia. This looks attractive in VEGF/IO refractory disease instead of evero. Combos earlier in the disease awaited.
6
60
142
33,921
Kelly Fitzgerald retweeted
22 Oct 2023
#Goosebumps #EV302 #ESMO23
Took 3 decades but a new SOC in 1L bladder cancer !!!!!! @tompowles1
EV Pembro irrespective…..WOW! 🤩
9
148
601
61,817
Kelly Fitzgerald retweeted
Top 5 #kidneycancer abstracts not to miss @myESMO #ESMO23! Belzutifan is everywhere and there's a phase 3 VEGF-IO trial reading out in a Chinese population!!
Looking forward to seeing all these data! @KidneyCancer @kcCURE @kidneycan @KCPUTSW @OncoAlert
1
37
82
8,384